Invivo Stock Today

NVIV -  USA Stock  

USD 0.47  0.03  6.00%

Market Performance
0 of 100
Odds Of Distress
Over 89
Invivo Therapeutics is selling for under 0.47 as of the 21st of January 2022; that is -6 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.46. Invivo Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Invivo Therapeutics Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of February 2020 and ending today, the 21st of January 2022. Click here to learn more.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . InVivo Therapeutics Holdings Corp. The company has 34.26 M outstanding shares of which 2.9 M shares are now shorted by private and institutional investors with about 3.5 trading days to cover. More on Invivo Therapeutics Holdings

Invivo Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Invivo Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Invivo Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Invivo Therapeutics generated a negative expected return over the last 90 days
Invivo Therapeutics has some characteristics of a very speculative penny stock
Invivo Therapeutics has high historical volatility and very poor performance
Invivo Therapeutics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (9.18 M) with profit before overhead, payroll, taxes, and interest of 0.
Invivo Therapeutics Holdings currently holds about 21.1 M in cash with (8.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Invivo Therapeutics has a poor financial position based on the latest SEC disclosures
Latest headline from www.bioworld.com: Clinical hold clutches Dynes stock - BioWorld Online
Legal NameInvivo Therapeutics Holdings
Chairman and CEOMark Perrin  (View All)
Average Analyst Recommendation
Analysts covering Invivo Therapeutics report their recommendations after researching Invivo Therapeutics' financial statements, talking to executives and customers, or listening in on Invivo Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Invivo Therapeutics. The Invivo consensus assessment is calculated by taking the average forecast from all of the analysts covering Invivo Therapeutics.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Invivo Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Invivo Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 4 - PoorDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares22.1 M27.9 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted22.2 M27.9 M
Significantly Down
Increasing
Slightly volatile
Total Assets33.8 M31.3 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities10.2 M6.7 M
Way Up
Decreasing
Slightly volatile
Current Assets32.9 M30.5 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities5.7 M5.6 M
Fairly Up
Decreasing
Slightly volatile
Total Debt1.1 M1.2 M
Sufficiently Down
Increasing
Very volatile
Return on Average Assets(80.46)(74.57)
Significantly Down
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Invivo Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Invivo Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Invivo Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Invivo Therapeutics' financial leverage. It provides some insight into what part of Invivo Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Invivo Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Invivo Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Invivo Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 914 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Invivo Therapeutics has a current ratio of 10.43, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(20.77 Million)Share
Invivo Therapeutics Holdings (NVIV) is traded on NASDAQ Exchange in USA and employs 6 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 17.13 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Invivo Therapeutics's market, we take the total number of its shares issued and multiply it by Invivo Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Invivo Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 34.26 M outstanding shares of which 2.9 M shares are now shorted by private and institutional investors with about 3.5 trading days to cover. Invivo Therapeutics Holdings currently holds about 21.1 M in cash with (8.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Invivo Therapeutics Probability Of Bankruptcy
Ownership
Invivo Therapeutics secures a total of 34.26 Million outstanding shares. Roughly 86.0 (percent) of Invivo Therapeutics outstanding shares are held by regular investors with 2.17 % owned by insiders and only 11.59 pct. by outside corporations. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Invivo Ownership Details

Invivo Stock Price Odds Analysis

What are Invivo Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Invivo Therapeutics jumping above the current price in 90 days from now is roughly 97.0%. The Invivo Therapeutics Holdings probability density function shows the probability of Invivo Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Invivo Therapeutics has a beta of 0.8548. This indicates Invivo Therapeutics Holdings market returns are correlated to returns on the market. As the market goes up or down, Invivo Therapeutics is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Invivo Therapeutics is significantly underperforming DOW.
 Odds Down 0.47HorizonTargetOdds Up 0.47 
3.42%90 days
 0.47 
96.55%
Based on a normal probability distribution, the odds of Invivo Therapeutics to move above the current price in 90 days from now is roughly 97.0 (This Invivo Therapeutics Holdings probability density function shows the probability of Invivo Stock to fall within a particular range of prices over 90 days) .

Invivo Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Invivo Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Invivo Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Invivo Therapeutics' value.
InstituionSecurity TypeTotal SharesValue
Ims Capital ManagementCommon Shares20.1 KK
Blackrock IncCommon Shares867.8 K607 K
View Invivo Therapeutics Diagnostics

Invivo Therapeutics Historical Income Statement

Invivo Therapeutics Holdings Income Statement is one of the three primary financial statements used for reporting Invivo's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Invivo Therapeutics revenue and expense. Invivo Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Invivo Therapeutics Operating Expenses is fairly stable at the moment as compared to the past year. Invivo Therapeutics reported Operating Expenses of 13.22 Million in 2021. Research and Development Expense is likely to climb to about 7.9 M in 2022, whereas Earning Before Interest and Taxes EBIT is likely to drop (11.2 M) in 2022. View More Fundamentals

Invivo Stock Against Markets

Picking the right benchmark for Invivo Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Invivo Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Invivo Therapeutics is critical whether you are bullish or bearish towards Invivo Therapeutics Holdings at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Invivo Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now

   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Invivo Therapeutics Corporate Directors

Invivo Therapeutics corporate directors refer to members of an Invivo Therapeutics board of directors. The board of directors generally takes responsibility for the Invivo Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Invivo Therapeutics' board members must vote for the resolution. The Invivo Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Additionally, see Stocks Correlation. Note that the Invivo Therapeutics information on this page should be used as a complementary analysis to other Invivo Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Invivo Stock analysis

When running Invivo Therapeutics price analysis, check to measure Invivo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invivo Therapeutics is operating at the current time. Most of Invivo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invivo Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Invivo Therapeutics' price. Additionally, you may evaluate how the addition of Invivo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Is Invivo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Invivo Therapeutics. If investors know Invivo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Invivo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Invivo Therapeutics is measured differently than its book value, which is the value of Invivo that is recorded on the company's balance sheet. Investors also form their own opinion of Invivo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Invivo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invivo Therapeutics' market value can be influenced by many factors that don't directly affect Invivo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invivo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Invivo Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invivo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.